Yeah, that's exactly it. Musick is a research scientist at heart, and I think he's in this for more than a pay day. But nobody is going to tell me that Zamora and the others are not in this primarily to make a lot of money. To do that, they need to create shareholder value. And since 2018 I think they have played most of their cards as well as we could expect. Delisting is never a great thing, but it's clear that it happened in the context of a broader plan. TBH, the only thing they have done in recent years that has me shaking my head is the GIOSTAR deal. I know nothing about those people, but their web sites reek of "charlatan stem cell company". I don't see what VB got out of a relationship with them. I mean, if there was ever a time where contacts in India might be useful, you'd think it would be now, since COVID-19 is out of control there. But I don't see any sign of any activity. Maybe it helped behind the scenes with the FDA study or something. But on the surface it doesn't make any sense.
